WORKING DRAFT: NOT FOR CITATION, QUOTATION OR DISTRIBUTION

Review of Seresto Pet Collar Incidents Data

Presentation for Bayer June 9th, 2016

U.S. Environmental Protection Agency
Office of Pesticide Programs
Health Effects Division (HED)

Seresto Overview

- Seresto: pet collar (dog & cat) containing 4.5% flumethrin and 10.0% imidacloprid
 - Intended to provide 8 months of control for fleas and ticks
- Submitted on September 23, 2010 as part of a new AI; Non-Food; Indoor Use submission for flumethrin
 - Seresto (EPA Reg. No. 11556-155) is currently the only registered enduse product for flumethrin
- Registered on March 16, 2012
- Currently Pending Registration with PMRA
 - · Working closely with PMRA on analysis
 - Reviewed PMRA's Plausibility Analysis
 - Will review PMRA's Causality Analysis
- In Europe there are 4 Seresto collars authorized: one for cats, one for cats and dogs, one for small dogs (<8kg), and one for large dogs (>8kg).

WORKING DRAFT: NOT FOR CITATION, OUDTATION OR DISTRIBUTION

Seresto Incident Review

- OPP review of pet incidents by product in IDS query
- HED reviewed Seresto collar incident data using 4 levels:
 - 1. Incident counts reported to Aggregate IDS
 - 2. Reporting Odds Ratio (ROR)
 - 3. Incident Rate Ratio (IRR)
 - 4. Additional analyses, by VedDRA code symptom
- Additionally, HED reviewed the most recent Bayer quarterly data for seasonal trends

WORKING DRAFT: NOT FOR CITATION, QUOTATION OR DISTRIBUTION

The query in the above was Jan 1, 2012-July 29 2015. This graph is included merely to illustrate why OPP got worried about Seresto

Level 1. IDS Aggregate Query Results from CY 2013 – 2014

In terms of incident counts, Seresto ranked #1, for death + major incident counts in IDS among Bayer products;

	190	627	8709	9526
	223	513	11303	12039
A second control of the second	112	242	3907	4261
A contract of the contract of	86	187	2003	2276
	38	5	141	184

Limitations:

- Pet incident reports are counts, by severity
 - species unknown
- Not normalized
- No descriptive detail available

WORKING DRAFT: NOT FOR CITATION, QUOTATION OR DISTRIBUTION

Top three products Seresto Frontline plus for dogs Frontline plus for cats

Level 2. Reporting Odds Ratio

- Reporting Odds Ratio (ROR) calculated for all pet Spot On products with ten or more deaths reported in IDS
- ROR measures the odds of fatal or high severity incidents for Seresto compared to the odds of fatal or high severity incidents for all other products
- Calculation:
 - 1. X = death + major incident reports for Product A / all other (less severe) incident reports for Product A
 - 2. Y = death + major incident reports for all other (not Product A) products / all other (not Product A) less severe incident reports
 - 3. ROR = X/Y

WORKING DRAFT: NOT FOR CITATION, QUOTATION OR DISTRIBUTION

Level 2. Reporting Odds Ratio

Benefits and Limitations

- · Does not require sales data
- Incident data issues with using counts:
 - · Pet product labeling is inconsistent
 - Seresto = 1 registration # for all species/sizes combined
 - Other products have multiple registration #s by species, animal size
 - Hence, IDS reports, which are organized by product registration #, do not reflect these important distinctions

WORKING DRAFT: NOT FOR CITATION, QUOTATION OR DISTRIBUTION

ć

combined the following:

Advantage II for cats (11556-150 – kitten, 1156-151 – small cat, 11556-152 – large cat),
Advantage II for dogs (11556-128 – small dog, 11556-125 – medium dog, 11556-127 - large dog, and 11556-130 – extra-large dog)

K9 Advantix II (11556-132 – small dog, 11556-133 medium dog, 11556-134 extra-large dog, 11556-135 large dog)

Reporting Odds Ratio

ROR Results for **Deaths Only** – Bayer product comparison

EAR Constration	Description	OC.		
	190	9526	0.81	(0.68, 0.96)
11556 144 1453 142 145 Advanta II	223	12039	0.70	(0.60, 0.83)
A Company of Company	112	4261	1.18	(0.96, 1.45)
(11556- 127, 130, 128, 125) Advantage plus dogs	86	2276	1.77	(1.41, 2.24)
	38	184	11.71	(8.12,16.88)

WORKING DRAFT: NOT FOR CITATION, QUOTATION OR DISTRIBUTION

We calculated ROR for all pet products with 10 or more deaths- this table is the top three products in terms of pet deaths + major

IDS data from 2013/2014 was originally used ***These ROR have been updated with more recent data***
K9 product only includes large dog
Frontline for dogs

Reporting Odds Ratio

ROR Results for <u>Deaths + Major Incidence</u> – Bayer product comparison

EPA Registration Number and Product Name	Death Major nessence	Fotal.	ROR	
Security (817	9526	1.16	(1.06, 1.27)
	736	12039	0.65	(0.59, 0.71)
	354	4261	1.07	(0.95, 1.21)
(11556- 127, 130, 128, 125) Advantaga plus dogs	273	2276	1.68	(1.47, 1.92)
	43	184	3.63	(2.57, 5.12)

WORKING DRAFT: NOT FOR CITATION, QUOTATION OR DISTRIBUTION

We calculated ROR for all pet products with 10 or more deaths- this table is the top three products in terms of pet deaths + major

IDS data from 2013/2014 was originally used ***These ROR have been updated with more recent data***
K9 product only includes large dog
Frontline for dogs

Level 3. Incident Rate Ratio (IRR)

- Seresto and other Bayer product sales data was obtained
- This allowed HED to:
 - · Calculate the Incident Rate Ratio
 - a standard method of comparing incident rates
 - Control for 8 months Seresto vs. 1 month Spot-On
 - IR_A = incident counts for Product A/ "pet-months"* for Product A
 - IR_B = incident counts for Product B/ "pet-months" for Product B
 - IRR = IR_A / IR_B
- Used the Poisson Regression Model (with "offset")
 - · Allows one to obtain confidence limits around IRR
 - Can determine statistically significant differences between products

WORKING DRAFT: NOT FOR CITATION, QUOTATION OR DISTRIBUTION

Seresto last 8 months = 8,000 pet months of exposure whereas Spot-ons = 1,000 pet months of exposure DRAFT - DO NOT CITE

^{*}Pet-months = sales x control period

Level 3. Incident Rate Ratio

Table: IRR comparison between Seresto and K9 Advantix II

Year	Outcome	Comparison	IRR (95% C.I)
2013+2014	Death + major	Seresto vs. K9 Advantix II Dog	3.10 (2.80, 3.42)
	Total Incidents	Seresto vs. K9 Advantix II Dog	2.21 (2.15, 2.27)

NOTE: HED did not have annual sales data for K9 Advantix II (HED had cumulative sales for 4 years (2011-2014) for K-9 Advantix II and derived approximate total 2013 and 2014 sales number by dividing the four year 2011-2014 total by 4 and then multiply by 2)

WORKING DRAFT: NOT FOR CITATION, QUOTATION OR DISTRIBUTION

18

Outcome Death Seresto vs. Frontline – 2014

IRR (95% C.I) = 16.55 (12.33, 22.21)

Need to consider limitations in data- reporting high severity cases for symptoms lasting 60 days or more whereas other registrants may classify rash etc as moderate –

Level 3. Incident Rate Ratio

Benefits:

- The most valid method of analysis
- Sales data incorporated


Limitations:

- Data inconsistencies
 - Seresto has one registration number for all collars
 - Sales data was approximated
 - Availability of sales information varied among products
 - Use of 2013/2014 data & the Weber Effect
 - Variability in reporting practices/categorizations by company –
 - But comparisons here only within Bayer

WORKING DRAFT: NOT FOR CITATION, QUOTATION OR DISTRIBUTION


3.3

<u>Level 4 Tree Diagram- Canine</u> data signals- Seresto, by symptom (VedDRA coded)



Multivariate tree diagram - check for signals Seresto- 817= deaths + majors GREEN BOXES DO NOT DIFFER FROM THE AVERAGE RISK Each box represents # of death+ majors, the height represents the deaths, and color represents the Reporting Odds Ratio

<u>Level 4 Tree Diagram -- Feline</u> data signals- Seresto, by symptom (VedDRA coded)



Multivariate tree diagram - check for signals Seresto- 817= deaths + majors GREEN BOXES DO NOT DIFFER FROM THE AVERAGE RISK Each box represents # of death+ majors, the height represents the deaths, and color represents the Reporting Odds Ratio


Recent Seresto Data Submission

- Third quarter 2015 Bayer incident data was received in October 2015.
- OPP noted a jump in death and major severity incidents for Q3
 - Increase from 185 incidents to 343 incidents
- HED compared Seresto and three other Bayer pet products using incident counts for the 6 most recent quarters of data
- · Based on newest available incident data
- Looking for a similar jump in incidents among other pet products that would indicate a seasonal trend


WORKING DRAFT: NOT FOR CITATION, QUOTATION OR DISTRIBUTION

16


In Mid-October, When Bayer submitted the 3rd quarter Seresto incidents there was an increase in deaths and majors. We compared the same 6 quarter for 4 bayer products to see if other products followed this trend or if it was just Seresto.



What happened? Is this normal? Well- the other products did not double from Q2 to Q3





What happened? Is this normal? Well- the other products did not double from Q2 to Q3



Combines all species and sizes for the non-Seresto Bayer products- paste in the product combo list!!

DRAFT - DO NOT CITE





Acute Toxicity Review

- Based on slow release of active ingredients, waivers were granted for oral tox, dermal tox, inhalation tox and eye irritation
- Not a dermal sensitizer
- Category IV for primary dermal irritation

WORKING BRAFT: NOT FOR CITATION, QUOTATION OR DISTRIBUTION

Companion Animal Safety Review

- Protocols were submitted and accepted prior to conducting studies
- A total of 8 companion animal safety studies were submitted
- Studies classified as acceptable; support the proposed use of Seresto on adult dogs and puppies 7 weeks of age and older, and adult cats and kittens 10 weeks of age and older

WORKING DRAFT: NOT FOR CITATION, QUOTATION OR

Efficacy Review

- A total of 20 studies were submitted
- Claim supported: "For 8 month prevention and treatment of ticks, fleas on dogs and cats"

WORKING DRAFT: NOT FOR CITATION, QUOTATION OR DISTRIBUTION

<u>Timeline of Initial Bayer Communications</u>

- 7/27/15: EPA received a press inquiry re: Seresto
 - "Is EPA aware of any incidents surrounding Seresto and are there any ongoing investigations?"
- 7/29/15; first call with Bayer
 - Objective of call was to ask if they are aware of a high number of reported incidents
- 7/30/15; second call with Bayer
 - Objective of call was to request submission of incident data
- 7/30/15; Bayer emails sample of enhanced reporting format
- 8/3/15; Bayer emails incident information that was originally submitted to PMRA and published information regarding "Weber Effect"
 - Format Issues

WORKING DRAFT: NOT FOR CITATION, QUOTATION OR DISTRIBUTION

Call with Bayer on 2015 Q3 incident data

• EPA- Why the jump in FY 15 Q3 major incidents?

Bayer Response:

- Large increase in collar sales in FY 15 Q2
 - Q3 incidents likely reflective of Q2 sales
 - Sales substantially above that of the previous quarter
- Bayer is conservative with high severity coding; 60% are moderate
 - >60 days dermal rash is classified as DB (major severity)
 - · Unclear how other registrants are coding

WORKING DRAFT: NOT FOR CITATION, QUOTATION OR DISTRIBUTION

20

DA - Death - if the domestic animal died or was euthanized:

DB – Major – if the domestic animal exhibited or was alleged to have exhibited symptoms which may have been life-threatening or resulted in residual disability;

DC – Moderate – if the domestic animal exhibited or was alleged to have exhibited symptoms which are more pronounced, more prolonged or of a more systemic nature than minor symptoms and included some treatment and return to pre-exposure state;

DD – Minor – if the domestic animal was alleged to have exhibited symptoms, but they were minimally bothersome and resolved rapidly;

DE - Unknown - if symptoms are unknown or not specified.

Limitations with Pet Product Incident Data

Potential confounders described by Bayer:

- Variability between companies
 - Bayer has a 24 hour reporting hotline
 - Differences among registrants regarding severity classification
- Variability between products
 - Weber effect
 - Seeing the collar each day serves to visually remind pet owners of the exposure
 - Seresto has one registration # for all species/sizes whereas other products can have a separate registration # for the species/sizes
- Is variability still an issue?
 - No issue of variability between companies if Seresto vs. Bayer's products
 - Weber effect should not be a concern for the data in recent years

FOR CITATION, QUOTATION OR

25

Advantage II for cats (11556-150 – kitten, 1156-151 – small cat, 11556-152 – large cat),

Advantage II for dogs (11556-128 – small dog, 11556-125 – medium dog, 11556-127 - large dog, and 11556-130 – extra-large dog)

K9 Advantix II (11556-132 – small dog, 11556-133 medium dog, 11556-134 extra-large dog, 11556-135 large dog)